S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
S&P 500   4,513.04
DOW   34,022.04
QQQ   387.12
OTCMKTS:ABVC

ABVC BioPharma Stock Forecast, Price & News

$2.96
-0.08 (-2.63%)
(As of 12/1/2021 04:00 PM ET)
Add
Compare
Today's Range
$2.93
$3.23
50-Day Range
$2.15
$6.03
52-Week Range
$1.95
$11.69
Volume
126,668 shs
Average Volume
1.05 million shs
Market Capitalization
$84.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.6
30 days | 90 days | 365 days | Advanced Chart
Receive ABVC News and Ratings via Email

Sign-up to receive the latest news and ratings for ABVC BioPharma and its competitors with MarketBeat's FREE daily newsletter.


ABVC BioPharma logo

About ABVC BioPharma

ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The firm's products pipeline include ABV-1501, which is a combination therapy for triple negative breast cancer (TNBC); ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine; ABV-1505 for treating attention deficit hyperactivity disorder (ADHD); ABV-1702 is to treat myelodysplastic syndromes (MDS); ABV-1703, for Pancreatic Cancer; ABV-1601 for treating depression in cancer patients; ABV-1701 is a vitreous substitute for vitrectomy; ABV-2001; and ABV-2002. The company was founded in 1990 and is headquartered in Fremont, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:ABVC
Fax
N/A
Employees
34
Year Founded
N/A

Sales & Book Value

Annual Sales
$480 thousand
Book Value
$0.11 per share

Profitability

Net Income
$-9.79 million
Net Margins
-2,145.77%
Pretax Margin
-2,282.14%

Debt

Price-To-Earnings

Miscellaneous

Free Float
14,419,000
Market Cap
$84.68 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/15/2021
Today
12/02/2021
Fiscal Year End
12/31/2021

MarketRank

Overall MarketRank

1.29 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












ABVC BioPharma (OTCMKTS:ABVC) Frequently Asked Questions

How has ABVC BioPharma's stock price been impacted by Coronavirus?

ABVC BioPharma's stock was trading at $2.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ABVC shares have increased by 2.1% and is now trading at $2.96.
View which stocks have been most impacted by COVID-19
.

How were ABVC BioPharma's earnings last quarter?

ABVC BioPharma, Inc. (OTCMKTS:ABVC) announced its quarterly earnings data on Monday, November, 15th. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of ($0.04) by $0.03. ABVC BioPharma had a negative trailing twelve-month return on equity of 318.25% and a negative net margin of 2,145.77%.
View ABVC BioPharma's earnings history
.

Who are ABVC BioPharma's key executives?

ABVC BioPharma's management team includes the following people:
  • Eugene Jiang, Chairman & Chief Business Officer
  • Howard Doong, President & Chief Executive Officer
  • Chih-Liang An, Chief Financial Officer
  • Chi-Hsin King, Chief Scientific Officer
  • Tsung-Shann Jiang, Director & Chief Strategy Officer

What is ABVC BioPharma's stock symbol?

ABVC BioPharma trades on the OTCMKTS under the ticker symbol "ABVC."

When does ABVC BioPharma's lock-up period expire?

ABVC BioPharma's lock-up period expires on Monday, January 31st. ABVC BioPharma had issued 1,100,000 shares in its initial public offering on August 3rd. The total size of the offering was $6,875,000 based on an initial share price of $6.25. After the expiration of ABVC BioPharma's lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Who are ABVC BioPharma's major shareholders?

ABVC BioPharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.19%), Squarepoint Ops LLC (0.07%) and Credit Suisse AG (0.04%).

Which major investors are buying ABVC BioPharma stock?

ABVC stock was purchased by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Squarepoint Ops LLC, and Credit Suisse AG.

How do I buy shares of ABVC BioPharma?

Shares of ABVC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ABVC BioPharma's stock price today?

One share of ABVC stock can currently be purchased for approximately $2.96.

How much money does ABVC BioPharma make?

ABVC BioPharma has a market capitalization of $84.68 million and generates $480 thousand in revenue each year.

How many employees does ABVC BioPharma have?

ABVC BioPharma employs 34 workers across the globe.

What is ABVC BioPharma's official website?

The official website for ABVC BioPharma is www.ambrivis.com.

Where are ABVC BioPharma's headquarters?

ABVC BioPharma is headquartered at 44370 Old Warm Springs Blvd, Fremont CA, 94538.

How can I contact ABVC BioPharma?

ABVC BioPharma's mailing address is 44370 Old Warm Springs Blvd, Fremont CA, 94538. The company can be reached via phone at (845) 291-1291.


This page was last updated on 12/2/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.